Solventum news
The WiseView Research desk's stories that name Solventum, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The SOLV page →
- HeadlineSOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy
- HeadlineSOLV Energy to Report Third Quarter 2026 Financial Results on November 12, 2026
- Company earningsThermo Fisher Scientific tops Q3 estimates, but shares slide premarket
Thermo Fisher beat EPS and revenue estimates for Q3, yet the stock fell before the open on October 21, 2026.
- HeadlineSolventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*
- HeadlineSolventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026
- HeadlineCan Solventum (SOLV) Keep the Earnings Surprise Streak Alive?
- HeadlineWhy Solventum (SOLV) is a Top Value Stock for the Long-Term
- CongressAlan Armstrong bought $1,001 - $15,000 of SOLV
- CongressRo Khanna bought $1,001 - $15,000 of SOLV
- CongressJames French Hill sold $15,001 - $50,000 of SOLV
- CongressRon Wyden sold $1,001 - $15,000 of SOLV
- CongressJulie Johnson sold $1,001 - $15,000 of SOLV
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.